In vitro activities of cefepime and cefpirome against 96 isolates of Chryseobacterium indologenes and 21 of C. meningosepticum were determined by the agar dilution method. Overall, cefepime was more active than cefpirome against C. indologenes (MIC at which 50% of the isolates were inhibited [MIC 50 ] and MIC 90 , 4 and 16 g/ml, respectively, for cefepime and 8 and 128 g/ml, respectively, for cefpirome). Both agents had poor potency against C. meningosepticum (MIC 50 and MIC 90 , 64 and >256 g/ml, respectively, for cefepime and 128 and >256 g/ml, respectively, for cefpirome).
Strains of Chryseobacterium species, including Chryseobacterium indologenes and C. meningosepticum, have been documented as human pathogens causing a variety of invasive infections, especially in hospitalized patients with severe underlying diseases who had indwelling devices implanted (3) (4) (5) (6) 11) . Appropriate choice of effective antimicrobial agents for treatment of infections caused by Chryseobacterium species is difficult because of the unpredictability and breadth of antimicrobial resistance of these organisms (1, 10) . The "fourthgeneration" cephalosporins (especially cefepime and cefpirome) have been demonstrated to have improved activity against a wide array of gram-positive and gram-negative bacteria, including nonfermentative gram-negative bacilli (2, 7, 9, 12) . However, data on the susceptibility of Chryseobacterium species to fourth-generation cephalosporins are limited (7) .
Ninety-six isolates of C. indologenes and 21 of C. meningosepticum recovered from various clinical specimens of 117 patients seen from January 1992 to June 1997 at the National Taiwan University Hospital were studied. These strains were identified in accordance with previous descriptions (4) . MICs for these isolates were determined by the agar dilution method by following National Committee for Clinical Laboratory Standards guidelines (8) and using Mueller-Hinton agar (BBL Microbiology Systems, Cockeysville, Md.) and a multipoint inoculator with an inoculum of 10 4 CFU per spot. Powdered cefepime with known potency was kindly provided by BristolMyers Squibb Laboratories (Princeton, N.J.), and powdered cefpirome was provided by Hoechst Marion Roussel (Frankfurt, Germany). Concentrations of the two drugs ranged from 0.03 to 256 g/ml. Plates were incubated at 35°C in ambient air, and MICs were read at 16 to 18 h.
The MICs of cefepime and cefpirome for five control strains were as follows: 0.03 and 0.06 g/ml, respectively, for Escherichia coli ATCC 25922; 2 and 2 g/ml, respectively, for Pseudomonas aeruginosa ATCC 27853; 2 and 1 g/ml, respectively, for Staphylococcus aureus ATCC 29213; 0.5 and 0.25 g/ml, respectively, for C. indologenes ATCC 29879; and 64 and 128 g/ml, respectively, for C. meningosepticum ATCC 13253. Table 1 shows data on the susceptibility of Chryseobacterium isolates to cefepime and cefpirome. Cefepime and cefpirome both had poor activity against isolates of C. meningosepticum. For C. indologenes isolates, cefpirome was less active, with MICs for 50 and 90% of the strains tested (MIC 50 and MIC 90 ) that were twofold and eightfold, respectively, higher than those of cefepime. When we applied the cefepime MIC breakpoints for organisms other than Haemophilus species, Neisseria gonorrhoeae, and Streptococcus species published by the National Committee for Clinical Laboratory Standards in M7-A4 of January 1997 (Յ8 g/ml, susceptible; 16 g/ml, intermediate; Ն32 g/ml, resistant) to those of cefepime and cefpirome against Chryseobacterium species (8), the susceptibilities of C. indologenes to cefepime and cefpirome were 73 and 64%, respectively.
The MICs obtained in the present study and those in our previous report (1) were compared, although some subtle differences in the MICs due to technical differences may exist because the two testings were performed at different times. Except for piperacillin, all of the extended-spectrum ␤-lactam antibiotics tested had poor activity against strains of C. meningosepticum (1). Unfortunately, C. meningosepticum is a welldocumented human pathogen causing severe infections, including meningitis, bacteremia, and catheter-related sepsis, complicating therapy especially in debilitated patients (11) . For C. indologenes isolates, cefepime was the most active agent among the eight ␤-lactam antibiotics tested, although the potency of these agents was not satisfactory. However, for treating infections caused by C. indologenes, the most commonly encountered Chryseobacterium species, piperacillin, ceftazidime, cefoperazone, and fourth-generation cephalosporins may be considered the drugs of choice (1, 11) .
Compared with expanded-spectrum cephalosporin susceptibility results for C. indologenes isolates tested previously (1), the MIC 50 or MIC 90 of cefepime was 1 log 2 dilution lower than that of ceftazidime and 8 or more log 2 dilutions lower than that of cefotaxime. The activity of cefpirome was equal to that of ceftazidime. Activities of cefepime and cefpirome against the C. indologenes isolates tested were approximately equal to those against P. aeruginosa (MIC 50 and MIC 90 , 4 and 32 g/ml, respectively, for cefepime and 2 and 128 g/ml, respectively, for cefpirome) (2, 7, 12) . Also, more than 90% of the isolates of C. indologenes and C. meningosepticum with intermediate or complete resistance to ceftazidime showed cross-resistance to cefepime or cefpirome. These findings were in accord with previous descriptions of P. aeruginosa (12) . The possibility of the presence of a novel ␤-lactamase such as an OXA-1-like ␤-lactamase, SHV-2 to SHV-6, and some extended TEM ␤-lactamases in Chryseobacterium isolates, like those of Enterobacteriaceae and P. aeruginosa, may contribute to this phenomenon and needs further investigation (12) .
In summary, cefepime was more active than cefpirome against the C. indologenes strains tested. Both cefepime and cefpirome had poor activity against C. meningosepticum strains. For treating infections caused by Chryseobacterium species, determination of the MIC for each individual isolate is mandatory. 
